ReviewRSC medicinal chemistry2026
Natural products in diabetic nephropathy: mechanisms and structure-activity relationships.
Review in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antioxidative and Anti-Inflammatory Mechanisms of Quercetin in the Prevention of Secondary Diabetes Complications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN), a major microvascular complication of diabetes mellitus, is a leading cause of end-stage renal disease and represents a significant threat to global public health. Currently, clinical management primarily relies on hypoglycemic, antihypertensive, and lipid-lowering agents. Although these therapies can slow the progression of DN, their overall efficacy remains limited due to adverse side effects, poor target specificity, and the multifactorial pathogenesis of the disease. Natural products, predominantly derived from medicinal plants, possess diverse chemical scaffolds and are characterized by multi-target pharmacological actions and broad therapeutic potential. These compounds exert beneficial effects through modulation of key pathological processes, including oxidative stress, inflammatory responses, autophagy, ferroptosis, and renal fibrosis. A literature search was conducted in PubMed and Web of Science for articles published between 2017 and 2025 using keywords including "diabetic nephropathy", "diabetic kidney disease", "natural products", "polyphenols", "phenolic acids", "flavonoids", "flavonols", "flavones", "isoflavones", "iridoids", "saponins", "triterpenoids", "lignans", "stilbenes", "curcuminoids", "quinones", "alkaloids", "phenylethanoid glycosides", "autophagy", "ferroptosis", "NLRP3 inflammasome", "NF-κB", "Nrf2", "PI3K/Akt", "TGF-β/Smad", and "mechanisms". The pharmacological mechanisms of major natural product classes in DN are summarized, covering oxidative stress, inflammation, autophagy, and ferroptosis pathways. In contrast to existing reviews, this study categorizes anti-diabetic nephropathy natural products by chemical scaffold and offers a preliminary structure-activity relationship (SAR) analysis, thereby elucidating the potential link between structural features and pharmacological mechanisms. This provides a new research direction for future target identification and the development of novel anti-diabetic nephropathy agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.